Drug intelligence / Profile preview

Tropocells

Development stage: Preclinical
Lead developer: Estar Medical
Modality: Cell Therapies
Administration: Topical

Overview

Tropocells is an autologous platelet-rich fibrin (PRF) product derived from a patient's own blood. It is designed for wound care, specifically for conditions such as diabetic foot ulcers. The product is prepared as a gel clot from the patient's blood and applied topically to the wound bed. Its therapeutic action is based on the release of a concentrated array of growth factors and cytokines from the platelets and fibrin matrix, which collectively stimulate tissue regeneration, angiogenesis, and cellular proliferation to promote wound healing.

Brand names: Tropocells

Beyond the preview

Go deeper on Tropocells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tropocells.

Explore the full profile